U.S. markets closed

Opiant Pharmaceuticals, Inc. (OPNT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
8.63-0.06 (-0.69%)
At close: 4:00PM EST

Opiant Pharmaceuticals, Inc.

233 Wilshirre Boulevard
Suite 280
Santa Monica, CA 90401
United States
310 598 5410
http://www.opiant.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees21

Key Executives

NameTitlePayExercisedYear Born
Dr. Roger CrystalPres, CEO & Director908.51k574.16k1976
Mr. David D. O'TooleChief Financial Officer564.7kN/A1959
Dr. Phil SkolnickChief Scientific Officer586.99k546.78k1947
Ben AtkinsVP of Communications & Investor RelationsN/AN/AN/A
Mr. Brian GormanGen. CounselN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for opioid overdose; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Santa Monica, California.

Corporate Governance

Opiant Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.